Scholarlink

Background <p>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, improves glycaemic control and body weight and may confer early hepatic benefits by reducing hepatic steatosis and fibrosis-related markers.</p> Objective <p>This real-world study evaluated early metabolic and hepatic effects of tirzepatide over 4 months in adults with type 2 diabetes mellitus (T2DM).</p> Methods <p>This retrospective cohort study included 132 adults with T2DM initiated on tirzepatide. Anthropometric, glycaemic, lipid and hepatic parameters—including aminotransferases, gamma-glutamyl transferase (GGT) and fibrosis-4 (FIB-4) index—were assessed at baseline (prior to first dose) and at 4-month follow-up. Patients receiving concomitant DPP-4 inhibitors were excluded. Paired two-tailed <i>t</i>-tests were used for analysis.</p> Results <p>After 4&#xa0;months, mean weight decreased by 9.8&#xa0;kg (− 10.6%), HbA1c by 1.05%, LDL-cholesterol by 14.2&#xa0;mg/dL (− 11.8%) and triglycerides by 27.6&#xa0;mg/dL (− 15.4%) (all <i>p</i> &lt; 0.001). Hepatic parameters improved significantly, with reductions in AST (− 15.5%), ALT (− 16.4%), GGT (− 20.3%) and FIB-4 score (− 0.24; − 16.9%; <i>p</i> = 0.003). A reduction in fibrosis risk category was observed in 38% of participants.</p> Conclusion <p>In routine clinical practice, tirzepatide was associated with early improvements in metabolic control and hepatic biomarkers over 4&#xa0;months, suggesting potential hepato-metabolic benefits in adults with T2DM. Longer prospective studies with imaging endpoints are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic and hepatic effects of tirzepatide in adults with type 2 diabetes: A 4-month real-world evaluation

  • 期刊论文

  • 发表日期：

    2026年3月24日

查看全文
  • Rajeev Chawla,
  • Shalini Jaggi,
  • Yejoor Chawla,
  • Chahat Jaggi,
  • Shubhaa Chawla,
  • Siddhant Trehan

摘要

Background

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, improves glycaemic control and body weight and may confer early hepatic benefits by reducing hepatic steatosis and fibrosis-related markers.

Objective

This real-world study evaluated early metabolic and hepatic effects of tirzepatide over 4 months in adults with type 2 diabetes mellitus (T2DM).

Methods

This retrospective cohort study included 132 adults with T2DM initiated on tirzepatide. Anthropometric, glycaemic, lipid and hepatic parameters—including aminotransferases, gamma-glutamyl transferase (GGT) and fibrosis-4 (FIB-4) index—were assessed at baseline (prior to first dose) and at 4-month follow-up. Patients receiving concomitant DPP-4 inhibitors were excluded. Paired two-tailed t-tests were used for analysis.

Results

After 4 months, mean weight decreased by 9.8 kg (− 10.6%), HbA1c by 1.05%, LDL-cholesterol by 14.2 mg/dL (− 11.8%) and triglycerides by 27.6 mg/dL (− 15.4%) (all p < 0.001). Hepatic parameters improved significantly, with reductions in AST (− 15.5%), ALT (− 16.4%), GGT (− 20.3%) and FIB-4 score (− 0.24; − 16.9%; p = 0.003). A reduction in fibrosis risk category was observed in 38% of participants.

Conclusion

In routine clinical practice, tirzepatide was associated with early improvements in metabolic control and hepatic biomarkers over 4 months, suggesting potential hepato-metabolic benefits in adults with T2DM. Longer prospective studies with imaging endpoints are warranted.